Nucleophosmin mutations lead to abnormal, but reversible, nucleoli architecture and aggregate formation - implications for NPM1-targeting therapies in AML
Martin A. Grundy, Kellie Lucken, Xiaomeng Xing, Eva L. Simpson, Alice Worker, Ahmed Bayyoomi, Alison J. Beckett, Ian A. Prior, Daniel G. Booth, Claire Seedhouse
This study shows that NPM1 mutations cause abnormal nucleoli structure and reversible aggregates in AML, suggesting new therapeutic targets.
Journal of Cell Science · Apr 22, 2025Peer-reviewedCancer Biology